Shares of Advanced Accelerator Application SA (NASDAQ:AAAP) saw unusually-strong trading volume on Thursday . Approximately 72,599 shares traded hands during trading, an increase of 25% from the previous session’s volume of 57,875 shares.The stock last traded at $30.44 and had previously closed at $30.23.

Several equities analysts have commented on AAAP shares. Zacks Investment Research lowered shares of Advanced Accelerator Application SA from a “buy” rating to a “sell” rating in a research report on Tuesday, June 28th. Citigroup Inc. reiterated a “neutral” rating and set a $36.00 price objective (up previously from $32.00) on shares of Advanced Accelerator Application SA in a research report on Wednesday, March 16th. Finally, Canaccord Genuity reiterated a “buy” rating on shares of Advanced Accelerator Application SA in a research report on Tuesday, May 31st. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $35.67.

The stock’s market cap is $1.14 billion. The firm’s 50 day moving average is $29.77 and its 200 day moving average is $30.85.

Advanced Accelerator Application SA (NASDAQ:AAAP) last posted its earnings results on Friday, April 29th. The company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.20) by $0.11. On average, analysts expect that Advanced Accelerator Application SA will post ($0.46) EPS for the current year.

An institutional investor recently bought a new position in Advanced Accelerator Application SA stock. Alps Advisors Inc. purchased a new stake in Advanced Accelerator Application SA (NASDAQ:AAAP) during the fourth quarter, Holdings Channel reports. The firm purchased 50,816 shares of the company’s stock, valued at approximately $1,589,000. Alps Advisors Inc. owned about 0.15% of Advanced Accelerator Application SA at the end of the most recent quarter.

Advanced Accelerator Applications SA is a radiopharmaceutical company that develops, produces and sells molecular nuclear medicine (MNM), diagnostic and therapeutic products. The Company’s lead therapeutic candidate, Lutathera, is being developed for the treatment of midgut neuroendocrine tumors (NETs).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.